Style | Citing Format |
---|---|
MLA | Abadi RNS, et al.. "Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis." Current Pharmaceutical Design, vol. 31, no. 8, 2025, pp. 645-657. |
APA | Abadi RNS, Jazinaki MS, Bahari H, Rashidmayvan M, Amini MR, Aliakbarian M, Khodashahi R, Malekahmadi M (2025). Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Current Pharmaceutical Design, 31(8), 645-657. |
Chicago | Abadi RNS, Jazinaki MS, Bahari H, Rashidmayvan M, Amini MR, Aliakbarian M, Khodashahi R, Malekahmadi M. "Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis." Current Pharmaceutical Design 31, no. 8 (2025): 645-657. |
Harvard | Abadi RNS et al. (2025) 'Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis', Current Pharmaceutical Design, 31(8), pp. 645-657. |
Vancouver | Abadi RNS, Jazinaki MS, Bahari H, Rashidmayvan M, Amini MR, Aliakbarian M, et al.. Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Current Pharmaceutical Design. 2025;31(8):645-657. |
BibTex | @article{ author = {Abadi RNS and Jazinaki MS and Bahari H and Rashidmayvan M and Amini MR and Aliakbarian M and Khodashahi R and Malekahmadi M}, title = {Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis}, journal = {Current Pharmaceutical Design}, volume = {31}, number = {8}, pages = {645-657}, year = {2025} } |
RIS | TY - JOUR AU - Abadi RNS AU - Jazinaki MS AU - Bahari H AU - Rashidmayvan M AU - Amini MR AU - Aliakbarian M AU - Khodashahi R AU - Malekahmadi M TI - Impact of Melatonin Supplementation on Glycemic Parameters in Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis JO - Current Pharmaceutical Design VL - 31 IS - 8 SP - 645 EP - 657 PY - 2025 ER - |